Skip to main content
. 2022 Apr 20;13:822272. doi: 10.3389/fimmu.2022.822272

Figure 2.

Figure 2

Metabolic analysis comparing long-term elite controller (LTEC)-extreme and no-LTEC. (A) Orthogonal principal component analysis (ortho-PCA) of the 78 metabolites between LTEC-extreme and no-LTEC. (B) Metabolic enrichment pathways associated with the metabolites differentially expressed in the LTEC-extreme group [Kyoto Encyclopedia of Genes and Genomes (KEGG) database]. The x-axis indicates the impact of selected metabolites in the presented pathway, while the y-axis shows the level of enrichment of the pathway. (C) Illustration of the principal significant metabolites between LTEC-extreme and no-LTEC in the tricarboxylic acid (TCA) cycle (column bars indicating differences in relative plasma concentrations of those metabolites implicated in the Krebs cycle; white bar represents no-LTEC; gray bars represent LTEC-extreme [mean + SEM data]. *P < 0.05; **P < 0.01 (adapted from “Kreb’sCycleTemplate,” by BioRender.com (2021); retrieved from https://app.biorender.com/biorender-templates). (D) Logistic regression and receiver operator characteristic (ROC) curves elucidated the statistically significant metabolomics profile from the combination of 7 statistically significant TCA cycle metabolites as main differentiators between LTEC-extreme and no-LTEC-losing [area under the curve (AUC) = 0.957].